文献速递胸部肿瘤放疗姑息放疗与转移瘤

小细胞肺癌序贯免疫化疗后放疗的症状性放射性肺炎风险:多中心回顾性队列研究

The risk of symptomatic radiation pneumonitis in small cell lung cancer patients following sequential immunochemotherapy and radiotherapy: a multicenter retrospective cohort study.
PubMed 文献 · Radiat Oncol · 2025-12-05

该多中心回顾性队列纳入443例完成胸部调强或容积旋转调强放疗的小细胞肺癌患者,主要终点为2级及以上放射性肺炎(RP2+)发生率。随访(15.8±4.6)周内RP2+发生与男性、同步放化疗正相关,与VO2max负相关;放疗前免疫化疗、基础肺病及吸烟史未显示显著关联。

要点

  • 443例SCLC序贯免疫化疗后胸部放疗,RP2+发生与男性及同步放化疗正相关。
  • VO2max为RP2+独立负相关预测因子,SHR 0.92(0.86-0.98)。
  • 放疗前免疫化疗、基础肺病、吸烟史与RP2+无显著关联。

核心结论

  • 小细胞肺癌序贯免疫化疗后放疗的RP2+发生率与男性、同步放化疗正相关,与VO2max负相关。

研究设计与样本

  • 多中心回顾性队列研究,纳入两家医院443例完成胸部调强放疗或容积旋转调强放疗的小细胞肺癌患者,放疗时间2022年4月1日至2025年3月31日。
  • 主要终点为2级及以上放射性肺炎发生率,采用Fine-Gray竞争风险回归分析危险因素。

主要发现

  • 随访(15.8±4.6)周内,87例(19.6%)发生2级、35例(7.9%)发生3级、6例(1.4%)发生4级放射性肺炎。
  • 6例死于非放射性肺炎相关疾病者作为竞争事件处理。
  • 单因素分析中男性、尘肺、ECOG状态、同步放化疗与RP2+正相关,SHR分别为1.81(1.29-2.55)、2.56(1.35-4.87)、1.53(1.17-1.99)、2.15(1.35-3.42),均P<0.05。
  • 单因素分析中VO2max、LVEF、FEV1与RP2+负相关,SHR分别为0.89(0.84-0.935)、0.98(0.96-1.00)、0.34(0.19-0.61),均P<0.05。
  • 多因素竞争风险分析显示男性、同步放化疗、VO2max为RP2+独立预测因子,SHR分别为1.84(1.22-2.78)、1.72(1.04-2.87)、0.92(0.86-0.98),均P<0.05。

关键数值与推荐

  • 放疗前免疫化疗、既存肺部合并症及吸烟史均不是RP2+的显著指示因素(P>0.05)。

临床怎么用

  • 对男性及接受同步放化疗的小细胞肺癌患者应加强RP2+监测与预防。
  • VO2max较高者RP2+风险较低,可作为风险分层参考指标。

局限性

  • 回顾性研究设计,随访时间较短(15.8±4.6周),仅来自两家医院。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Immune checkpoint inhibitors plus thoracic radiotherapy (RT) may magnify the radiation pneumonitis (RP) risk. Data on the risk for symptomatic RP in small cell lung cancer (SCLC) patients following RT after induction immunochemotherapy using anti-programmed cell death protein-1 monoclonal antibody Serplulimab, cisplatin plus etoposide are limited. METHODS: This retrospective study included 443 SCLC patients from two hospitals who finished thoracic intensity-modulated radiation therapy or volumetric modulated arc therapy between April 1, 2022 and March 31, 2025. The primary endpoint was the incidence of grade 2 or worse (grade 2+) RP. Fine-Gray competing risks regression analyses were used to identify the potential risk factors of RP2+. RESULTS: The follow-up duration was (15.8 ± 4.6) weeks since the end of RT. In detail, 87 (19.6%), 35 (7.9%), and 6 (1.4%) patients developed grade 2, grade 3, and grade 4 RP respectively. Six patients died from non-RP-related diseases were treated as competing events. On univariate analysis, male, pneumoconiosis, ECOG status, concurrent chemoradiotherapy (CCRT) were positively correlated with the incidence of RP2+, with subdistribution hazard ratio (SHR) and 95% confidence interval (CI) of 1.81 (1.29-2.55), 2.56 (1.35-4.87), 1.53 (1.17-1.99) and 2.15 (1.35-3.42), respectively (all P < 0.05), while VO2max, left ventricular ejection fraction (LVEF), and forced expiratory volume in one second (FEV1) were negatively correlated with RP2+, with SHR and 95%CI of 0.89 (0.84-0.935), 0.98 (0.96-1.00), and 0.34 (0.19-0.61), respectively (all P < 0.05). Further multivariate competing risks analysis revealed that male, CCRT, and VO2max were independent predictors of RP2+, with SHR and 95% as 1.84 (1.22-2.78), 1.72 (1.04-2.87), and 0.92 (0.86-0.98), respectively (all P < 0.05). Additionally, immunochemotherapy before RT, preexisting pulmonary co-morbidities and smoking history were not significant indicators of RP2+ (P > 0.05, respectively). CONCLUSION: The incidence of RP2 + following sequential immunochemotherapy and RT was positively associated with male and CCRT, but negatively correlated with VO2 max in SCLC patients. CLINICAL TRIAL NUMBER: Not applicable.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Liu Y, Zhang J, Zhang M, et al. The risk of symptomatic radiation pneumonitis in small cell lung cancer patients following sequential immunochemotherapy and radiotherapy: a multicenter retrospective cohort study. Radiat Oncol. 2025. PMID: 41350861. doi:10.1186/s13014-025-02774-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。